Amy Hay is the Chief Business Officer at CTMC, a joint venture between MD Anderson Cancer Center and National Resilience accelerating cell therapy development from discovery to clinical translation.
At CTMC, Amy leads business strategy and partnerships, helping early-stage biotech companies navigate the complex journey from preclinical research to commercialization by providing end-to-end manufacturing, regulatory expertise, and clinical access—all under one roof.
Before joining CTMC, Amy served as Global Head of Oncology Strategic Initiatives at Varian, a Siemens Healthineers company, where she launched Oncology as a Service, a global platform integrating medical technology, clinical solutions, and digital services to expand access to advanced cancer care. Under her leadership, Varian forged partnerships with Ayala Health in the Philippines and CHRISTUS Health in the U.S., generating more than $75 million in new revenue within the program's first year.
Amy is also a founder, having founded Evolve International, a healthcare strategy firm advising leading cancer organizations across academic medicine, medtech, pharma, and digital health.
.png)
.png)